293294-72-1

Usage

Uses

Used in Organic Synthesis:
4-bromo-6-(methoxycarbonyl)picolinic acid is used as a key intermediate in the synthesis of complex organic molecules. Its bromine atom and methoxycarbonyl group facilitate various chemical reactions, enabling the formation of a wide range of organic compounds with diverse applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-bromo-6-(methoxycarbonyl)picolinic acid is utilized as a starting material for the development of new drugs. Its potential biological activity and unique structure make it a promising candidate for drug discovery and optimization. Researchers are investigating its potential applications in the treatment of various diseases and conditions.
Used in Drug Development:
4-bromo-6-(methoxycarbonyl)picolinic acid is employed as a building block in the synthesis of drug candidates. Its unique structure and functional groups allow for the creation of novel compounds with potential therapeutic effects. Ongoing research is focused on exploring its potential in the development of new drugs with improved efficacy and safety profiles.

Upstream product

• 67-56-1 methanol 
• 162102-81-0 4-bromopyridine-2,6-dicarboxylic acid 
• 112776-83-7 diethyl 4-bromo-2,6-pyridinedicarboxylate 
• 499-51-4 Chelidamic acid 
• 162102-79-6 dimethyl 4-bromo-2,6-pyridinedicarboxylate 

Downstream Products

• 885326-87-4 methyl 4-bromo-6-((tert-butoxycarbonyl)amino)picolinate 
• 885326-88-5 methyl 6-amino-4-bromo-pyridine-2-carboxylate 

Relevant academic research and scientific papers

SUBSTITUTED PYRIDINE COMPOUNDS AS PESTICIDES

The present invention relates to novel substituted pyridine compounds of the formula (I) in which R1, R2, R3, R4, R5, R6, V1, V2 and Q1 have the definitions

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY

The present invention relates to a compound of general formula I: wherein: n1 and n2 are the same or different, and are 0 or 1; R is aryl, heteroaryl, etc.; Re is hydrogen atom or lower alkyl; two groups selected from four groups consisting of (i) either

Effect of a halogenide substituent on the stability and photophysical properties of lanthanide triple-stranded helicates with ditopic ligands derived from bis(benzimidazolyl)pyridine

Bis {1-ethyl-2-[6-(N,N-diethylcarbamoyl)-4-halogenopyridin-2-yl]benzimidazol-5-yl} methane (halogeno = chloro, LE; bromo, LF) have been synthesized as ditopic receptors for the development of lanthanide-containing helicates able to couple with biological material and to test the influence of the halogeno substituent on the wrapping process, the structure of the resulting dimetallic edifices, and the photophysical properties of the encapsulated ions. The stability of the [Eu2(L)3]6+ helicates, as determined by NMR competitive titrations, decreases by respectively one (LF) and three (LE) orders of magnitude compared to the value found for the unsubstituted ligand (LB) although it remains large, log β23 = 23.8 (LF) and 21.8 (LE) in acetonitrile. The [Ln2(LE)3]6+ helicates are shown to be isostructural in acetonitrile over the lanthanide series (Pr to Yb) and the crystal structure of [Tb2(LB)3]6+ appears to be a good model for their solution structure, as demonstrated by paramagnetic NMR measurements (lanthanide induced shift method) and relaxation time determination. Ligand LE appears to be a fair sensitiser of EuIII, the quantum yield of [Eu2(LE)3]6+ being 25% larger than that found for [Eu2(LB)3]6+, but the ligand 3ππ* state and Tb(5D4) excited level are in resonance, which limits the sensitisation of TbIII. High resolution luminescence spectra of [Eu2(LE)3]6+, both in solution and in the solid state, are presented and discussed in terms of site symmetry and vibronic coupling mechanisms. The Royal Society of Chemistry 2000.